Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.65 |
| ▸ | CTSS | P25774 | 3/20 | 0.58 |
| ▸ | CTSK | P43235 | 3/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 6/20 | 0.57 |
| ▸ | PPARG | P37231 | 5/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.54 |
| ▸ | ITGAV | P06756 | 1/20 | 0.54 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501894 | 1.00 | ACE (0.65) | ACECTSSCTSKCTSLCTSB | |
| SCHEMBL24725329 | 1.00 | ACE (0.65) | ACECTSSCTSKCTSLCTSB | |
| SCHEMBL3500404 | 0.91 | KLK5 (0.61) | ACECTSSCTSKCTSLCTSB | |
| SCHEMBL3500399 | 0.91 | KLK5 (0.61) | ACECTSSCTSKCTSLCTSB | |
| SCHEMBL66220 | 0.89 | ACE (0.79) | ACECTSSCTSKCTSLCTSB | |
| SCHEMBL606309 | 0.89 | ACE (0.79) | ACECTSSCTSKCTSLCTSB | |
| SCHEMBL67020 | 0.89 | ACE (0.79) | ACECTSSCTSKCTSLCTSB | |
| SCHEMBL795685 | 0.89 | ACE (0.79) | ACECTSSCTSKCTSLCTSB | |
| SCHEMBL21473784 | 0.89 | ACE (0.79) | ACECTSSCTSKCTSLCTSB | |
| SCHEMBL27909397 | 0.89 | ACE (0.79) | ACECTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | ACE 4501/4885CTSS 3589/4885CTSK 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.